Biocept, Inc., a molecular diagnostics company, has launched liquid Biopsy test for Breast and Lungs Cancer. It will help physicians identify patients who may be receptive to certain breast and lung cancer treatments.
“The launch of FGFR1 testing is part of our strategy to use liquid biopsy to transform the field of personalized medicine,” said Raaj Trivedi, Biocept’s VP of Commercial Operations.
View the full release here.